Table 2.
| Table 2a : Characteristics of the HF population | ||||||
|---|---|---|---|---|---|---|
| Parameter | All Subjects | ----------------------Age---------------------- | Linear Correlation | P-value | ||
| <60 | 60–69 | ≥70 | ||||
| Age at Randomization (yrs) | 2331 59 (51, 68) |
1214 51.5 (44.8, 56.1) |
640 64.4 (62.2, 67.2) |
477 75.3 (72.5, 78.7) |
||
| Weight (kg) | 2331 90 (76, 106) |
1214 97 (79, 114) |
640 88 (77, 102) |
477 82 (70, 93) |
−0.35 | <0.001 |
| Height (cm) | 2324 173 (166, 180) |
1211 173 (165, 180) |
637 173 (168, 180) |
476 173 (168, 179) |
−0.04 | 0.044 |
| BMI (kg/m2) | 2324 30 (26, 35) |
1211 32 (27, 38) |
637 29 (26, 33) |
476 27 (24, 31) |
−0.37 | <0.001 |
| HR at rest, clinic visit (bpm) | 2326 70 (63, 77) |
1212 72 (64, 80) |
638 68 (62, 75) |
476 68 (60, 75) |
−0.22 | <0.001 |
| Systolic BP (mmHg) | 2327 111 (100, 126) |
1213 110 (100, 122) |
639 112 (102, 127) |
475 118 (104, 130) |
0.12 | <0.001 |
| Diastolic BP (mmHg) | 2326 70 (60, 78) |
1213 70 (62, 80) |
638 70 (60, 78) |
475 68 (60, 76) |
−0.13 | <0.001 |
| LVEF (%) | 2327 25 (20, 30) |
1210 24 (20, 30) |
640 25 (20, 30) |
477 26 (21, 31) |
0.05 | 0.025 |
| Comorbidity Score | 2331 29 (14, 43) |
1214 29 (14, 43) |
640 33 (15, 46) |
477 43 (29, 43) |
0.23 | <0.001 |
| Table 2b: Characteristics of HF-ACTION patient population | ||||||
|---|---|---|---|---|---|---|
| Parameter | All Subjects | ----------------------Age---------------------- | P value | |||
| <60 | 60–69 | ≥70 | ||||
| Overall Group Size (N) | 2331 | 1214 | 640 | 477 | ||
| Female | 661 (28.4) | 393 (32.4) | 166 (25.9) | 102 (21.4) | <0.001 | |
| NYHA class | ||||||
| • II | 1477 (63.4) | 808 (66.6) | 393 (61.4) | 276 (57.9) | <0.001 | |
| • III | 831 (35.7) | 399 (32.9) | 241 (37.7) | 191 (40.0) | ||
| • IV | 23 (1.0) | 9 (0.6) | 6 (0.9) | 10 (2.1) | ||
| Race | ||||||
| • Black or African American | 749 (32.6) | 502 (42.2) | 158 (25.0) | 89 (18.7) | <0.001 | |
| • White | 1426 (62.1) | 619 (52.0) | 434 (68.8) | 373 (78.5) | ||
| • Other | 121 (5.3) | 69 (5.8) | 39 (6.2) | 13 (2.7) | ||
| Therapy | ||||||
| • ACEI/ARB | 2199(94.3) | 1159 (95.6) | 603 (94.2) | 437 (91.6) | 0.010 | |
| • Beta Blocker | 2203 (94.5) | 1163 (95.8) | 604 (94.4) | 436 (91.4) | <0.001 | |
| • Bi-V pacemaker | 419 (18.0) | 195 (16.1) | 120 (18.8) | 104 (21.8) | <0.001 | |
| • Pacemaker | 414 (17.8) | 149 (12.3) | 134 (20.9) | 131 (27.5) | <0.001 | |
| Ischemic HF Etiology | 1197 (51.4) | 456 (37.6) | 396 (61.9) | 345 (72.3) | <0.001 | |
| Comorbidity | ||||||
| • DM | 748 (32.1) | 352 (29.0) | 246 (38.4) | 150 (31.5) | <0.001 | |
| • COPD | 249 (10.8) | 89 (7.4) | 89 (13.4) | 71 (15.0) | <0.001 | |
| • PAD | 157 (7) | 43 (4) | 57 (9) | 57 (12) | <0.001 | |
In each cell, data presented are N followed by median (25th percentile, 75th percentile). P-value is for the hypothesis test that the linear correlation (of the parameter with age as a continuous variable) is zero. Abbreviations: BMI, body mass index; HR, heart rate; BP, blood pressure; LVEF, left ventricular ejection fraction
In each cell, data presented are n followed by percentage.
Abbreviations: NYHA, New York Heart Association; ACEI/ARB, ACE inhibitor or Angiotensin II receptor blocker; Bi-V pacemaker, biventricular pacemaker; HF, heart failure; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease.